Abstract 143P
Background
Oesophageal cancer is the sixth leading cause of cancer-related mortality with more than 90% of oesophageal cancer being squamous cell carcinomas (ESCC) in Asian countries. Prognosis of ESCC remains extremely poor and identification of better prognostic factors is an unmet need.
Methods
We investigated the immune- histochemical expression of Notch1, Notch2, Notch 3, HES-1 (Hairy enhancer of Split -1) (a downstream transcription factor) and p21 among ESCC and non-tumour controls. Non-tumour controls consisted of diagnostic biopsies of GERD patients in which Barrett’s and erosive esophagitis had been ruled out. We also investigated the association of these markers with clinico-pathological features and survival. We included 46 patients of ESCC and 42 controls. IHC markers were performed according to the standard guidelines and analysed with a semi-quantitative H –score (The H score was calculated as: H score= D X I with values ranging from 1-15).
Results
The median age was 60 (37-78 years). M:F ratio was 30: 16. 65.2 % were smokers and 19.6 % were tobacco chewers. 38 cases were locally advanced (Stage III) and 8 were metastatic at baseline. Palliative intent therapy was offered to 24 % and definitive therapy to 76%. An ECOG -PS of 1,2 and 3 was observed in 26, 16 and 4 patients respectively. At a median follow up of 50.67 months, the median overall survival was10.47 mon (range= 8.23-15.1) mon. Using a cut-off score of 7.5 to define positivity, NOTCH 1,2,3 as well as p21 were found to be significantly over-expressed in ESCC as compared to normal controls, while there was no difference in Hes1 expression. Location, grade, baseline metastases, duration of symptoms showed no association with NOTCH 1,2 or 3 positivity. On univariate analysis, male sex, age >60 years, smokers, ECOG-PS>1, Notch 3 H score was found significant. On multivariate analysis, smokers (HR = 3.53, p = 0.013), ECOG-PS>1 (HR = 2.88, p = 0.006) and Notch3 H score (HR = 2.38, p = 0.047) emerged as independent adverse prognostic factors.
Conclusions
NOTCH 1,2 and 3 are highly expressed in ESCC as compared to controls. Notch3 H score is an independent predictor of survival in ESCC and merits evaluation in larger studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Raja Pramanik.
Funding
Intramural Research Fund, Research Section, All India Institute of Medical Sciences, New Delhi.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract